Ambroxol Dosing in Hemodialysis Patients

Introduction to Ambroxol Dosing

The American Journal of Respiratory and Critical Care Medicine recommends that ambroxol 15 mg be administered after dialysis sessions to prevent premature drug removal and facilitate directly observed therapy in hemodialysis patients 1, 2

The fundamental principle for medication administration in end-stage renal disease (ESRD) patients on hemodialysis is to give medications after dialysis to avoid premature removal of the drug and to facilitate directly observed therapy (DOT), as suggested by the American Journal of Respiratory and Critical Care Medicine 1, 2
Ambroxol is a mucolytic agent typically dosed at 15-30 mg three times daily in patients with normal renal function, according to the American Journal of Respiratory and Critical Care Medicine 3
The 15 mg dose represents the lower end of the therapeutic range, which is appropriate for patients with renal impairment, as recommended by the MMWR Recommendations and Reports and the American Journal of Respiratory and Critical Care Medicine 4, 5

For drugs with significant renal elimination, dosing frequency should be reduced rather than the milligram dose per administration, as suggested by the American Journal of Respiratory and Critical Care Medicine 6, 3, 1
Hemodialysis patients typically receive medications 2-3 times weekly aligned with their dialysis schedule, according to the American Journal of Respiratory and Critical Care Medicine 1, 2
Administering ambroxol 15 mg immediately after each hemodialysis session (typically 3 times per week) prevents drug removal during dialysis and ensures adequate therapeutic levels between sessions, as recommended by the American Journal of Respiratory and Critical Care Medicine 1, 2
Do not administer ambroxol before dialysis sessions, as this wastes the dose through premature removal, as warned by the American Journal of Respiratory and Critical Care Medicine 1, 2